Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The document serves as a notification of a transaction involving a director or person discharging managerial responsibility, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific share transaction and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The only reported change is a personal share purchase by a company official.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It strictly details a compliance notification under Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investors
- Transaction Type: Purchase of Ordinary shares by Mr. S Dingemans.
- Volume: 40,000 shares.
- Price: £11.80 per share.
- Date: February 4, 2011.
- Significance: This is a routine disclosure of insider trading activity and does not reflect broader corporate strategy or financial performance.